4.1 Neuromuscular Blocking Agents & Reversal: Anticholinesterases vs Sugammadex

4.1 Neuromuscular Blocking Agents & Reversal: Anticholinesterases vs Sugammadex

Neuromuscular blocking agents (NMBAs) interrupt synaptic transmission at the neuromuscular junction (NMJ) to facilitate endotracheal intubation, optimize surgical exposure, and prevent patient-ventilator dyssynchrony. Mastery of NMJ receptor kinetics, Phase I versus Phase II depolarizing characteristics, non-depolarizing drug classes, pharmacologic reversal mechanisms, and quantitative objective monitoring is critical for NBCRNA NCE examination success.

---

1. Neuromuscular Junction Anatomy & Receptor Physiology

Transmission at the NMJ occurs when an action potential depolarizes the motor nerve terminal, opening voltage-gated P/Q-type calcium channels. Influx of $Ca^{2+}$ triggers exocytosis of synaptic vesicles, releasing acetylcholine (ACh) (~5,000–10,000 molecules per vesicle/quantum) into the 20–50 nm synaptic cleft. Acetylcholine rapidly diffuses across the cleft to bind postjunctional nicotinic acetylcholine receptors (nAChRs) concentrated on the crests of junctional folds.

Motor Nerve Terminal  ───[Ca2+ Influx]───► ACh Exocytosis (5,000-10,000 ACh/vesicle)
                                                 │
                                                 ▼
Synaptic Cleft        ───[Diffuses across 20-50 nm cleft]───► Rapid AChE Hydrolysis
                                                 │
                                                 ▼
Postjunctional Folds  ───[Binds 2 α-subunits simultaneously]───► Na+/Ca2+ Influx & Depolarization

Nicotinic Acetylcholine Receptor Subtypes

Prejunctional Nicotinic Receptors & Acetylcholine Mobilization

Prejunctional nicotinic receptors ($\alpha_3\beta_2$ and $\alpha_7$) reside on the presynaptic nerve terminal. Under high-frequency stimulation (tetanic trains), these receptors act as a positive feedback loop: ACh binding triggers the mobilization of reserve storage vesicles containing acetylcholine from the nerve interior to the active release zones.

• Non-depolarizing NMBAs competitively block these prejunctional receptors, impairing ACh mobilization during rapid firing, which manifests clinically as Train-of-Four (TOF) and tetanic fade.
• Succinylcholine stimulates prejunctional receptors, maintaining ACh mobilization; hence, Phase I depolarizing block displays no fade.

---

2. Succinylcholine (Diacetylcholine): Depolarizing Blockade

Succinylcholine consists of two acetylcholine molecules joined by an ester linkage ($CH_3\text{-}COO\text{-}(CH_2)_2\text{-}N^+(CH_3)_3$). It is the only clinically used depolarizing NMBA, renowned for its rapid onset (30–60 seconds) and ultra-short duration (5–10 minutes) at standard doses of 1.0 to 1.5 mg/kg IV.

Phase I vs. Phase II Blockade Dynamics

Succinylcholine binds to one or both $\alpha_1$ subunits of the postjunctional nAChR, opening the ion channel and causing prolonged depolarization of the perijunctional endplate. Voltage-gated sodium channels in the perijunctional membrane rapidly inactivate and cannot repolarize, generating a zone of inexcitability that prevents action potential propagation.

Metabolism, Pseudocholinesterase & The Dibucaine Number

Succinylcholine is metabolized sequentially by pseudocholinesterase (also known as butyrylcholinesterase, plasma cholinesterase, or BChE), an enzyme synthesized exclusively by the liver and circulating in plasma. Pseudocholinesterase hydrolyzes succinylcholine into succinylmonocholine (which has 1/20th to 1/80th neuromuscular activity) and choline, and subsequently into succinic acid and choline.

$\text{Succinylcholine} \xrightarrow{\text{Plasma Cholinesterase}} \text{Succinylmonocholine} + \text{Choline} \xrightarrow{\text{Plasma Cholinesterase}} \text{Succinic Acid} + \text{Choline}$

Only a minute fraction (~10%) of the injected succinylcholine dose reaches the neuromuscular junction, as 90% is hydrolyzed intravascularly before arriving at the motor endplate. There is zero pseudocholinesterase in the synaptic cleft; termination of action at the NMJ occurs exclusively by passive diffusion of succinylcholine away from receptors back into the extracellular fluid and plasma.

The Dibucaine Test

Dibucaine is an amide local anesthetic that inhibits normal pseudocholinesterase activity by ~80%, but inhibits atypical genetic variants to a much lesser extent. The Dibucaine Number measures the percentage inhibition of pseudocholinesterase activity by dibucaine under standardized laboratory conditions. It reflects enzyme quality (function), NOT quantity.

Management of Atypical Pseudocholinesterase Paralysis: If a patient fails to recover spontaneous respiration following succinylcholine (or mivacurium), the CRNA must maintain sedation, analgesia, and controlled mechanical ventilation until twitches return spontaneously. Never administer neostigmine during Phase I paralysis, as it inhibits what little functional plasma cholinesterase remains and severely prolongs the blockade. Fresh frozen plasma (FFP) or purified butyrylcholinesterase contains active enzyme but is generally avoided due to transfusion risks.

Acquired Causes of Reduced Pseudocholinesterase Activity

Conditions that reduce circulating pseudocholinesterase levels (producing normal dibucaine number 70–80 but prolonged duration of action of 15–30 minutes):

• Severe hepatic parenchymal disease (cirrhosis, hepatitis, end-stage liver failure)
• Advanced pregnancy and immediate postpartum period (20–30% reduction)
• Severe malnutrition, cachexia, and end-stage malignancy
• Severe thermal burn injury (>24–48 hours post-injury)
• Renal failure / uremia
• Pharmacologic inhibitors: Organophosphate insecticides, echothiophate eye drops, neostigmine, pyridostigmine, esmolol, metoclopramide, oral contraceptives, monoamine oxidase inhibitors (MAOIs), and cytotoxic chemotherapeutic agents (cyclophosphamide).

Succinylcholine-Induced Hyperkalemia & Clinical Contraindications

In healthy patients, succinylcholine administration increases serum potassium by 0.5 mEq/L due to ion flux through mature postjunctional receptors. In patients with proliferated extrajunctional nAChRs, succinylcholine triggers massive, uncontrolled potassium efflux that can raise serum potassium by 3 to 10+ mEq/L, inducing ventricular fibrillation, electromechanical dissociation, and cardiac arrest refractory to standard resuscitation.

High-Risk Clinical Conditions and Safe Windows

Important Distinction on Precurarization: Administering a "defasciculating" dose of a non-depolarizing NMBA (e.g., rocuronium 0.03 mg/kg) prior to succinylcholine prevents visible muscle fasciculations and reduces postoperative myalgias, but it DOES NOT prevent hyperkalemic cardiac arrest in susceptible denervated or burn patients. Precurarization is never a substitute for avoiding succinylcholine in contraindicated populations.

Other Succinylcholine Adverse Effects & Systemic Toxicities

1. Cardiovascular Dysrhythmias: Succinylcholine stimulates muscarinic receptors in the cardiac sinus node and parasympathetic ganglia. Produces profound sinus bradycardia, nodal escape rhythms, or asystole, especially upon administration of a second IV dose in adults within 5–10 minutes or following the first dose in pediatric patients. Prevention/Treatment: Pretreatment with atropine (0.02 mg/kg IV).
2. Increased Intraocular Pressure (IOP): Increases IOP by 5 to 15 mmHg for 5 to 10 minutes due to tonic contraction of extraocular muscles and choroidal vascular engorgement. Historically contraindicated in open globe lacerations (risk of vitreous extrusion), although clinical risk with deep anesthesia and swift intubation remains debated.
3. Increased Intragastric Pressure (IGP) & Lower Esophageal Sphincter (LES) Tone: Increases IGP by 15–40 $\text{cmH}_2\text{O}$ due to abdominal fasciculations. Concurrently increases LES barrier pressure, maintaining the barrier pressure gradient in patients with intact sphincters. However, in incompetent LES (hiatal hernia, morbid obesity), aspiration risk is heightened.
4. Increased Intracranial Pressure (ICP): Transiently increases ICP via jugular venous engorgement and muscle spindle afferent stimulation; attenuated by defasciculating non-depolarizer doses and adequate anesthetic depth.
5. Masseter Muscle Rigidity (MMR): Transient, isolated jaw tightness occurs in ~1% of children. Exaggerated rigidity preventing mouth opening ("jaws of steel") is an early harbinger of Malignant Hyperthermia (MH) in 50% of cases.
6. Malignant Hyperthermia Trigger: Succinylcholine is a potent triggering agent for MH via defective Ryanodine Receptor-1 ($RYR1$) calcium release channels in skeletal muscle sarcoplasmic reticulum.

---

3. Non-Depolarizing NMBAs: Aminosteroids vs. Benzylisoquinolines

Non-depolarizing neuromuscular blocking agents act as competitive antagonists at the postjunctional nicotinic acetylcholine receptor. By occupying one or both $\alpha_1$ binding sites, they prevent endogenous acetylcholine from binding, preventing channel opening and endplate depolarization. At high concentrations, they can also cause non-competitive open-channel blockade.

Comparison of Non-Depolarizing Drug Classes

Hofmann Elimination Kinetics

Hofmann elimination is a purely non-enzymatic chemical process whereby a quaternary ammonium compound undergoes spontaneous molecular cleavage into a tertiary amine and an alkene at physiologic temperature and pH.

$\text{Cisatracurium} \xrightarrow{\text{pH } 7.4,\ 37^\circ\text{C}} \text{Laudanosine} + \text{Quaternary Monoacrylate}$

• Modifiers of Hofmann Elimination:
  • Acidosis ($pH < 7.35$) and Hypothermia ($T < 36^\circ\text{C}$) slow Hofmann elimination, significantly prolonging cisatracurium duration.
  • Alkalosis ($pH > 7.45$) and Hyperthermia ($T > 38^\circ\text{C}$) accelerate Hofmann elimination, shortening duration.
• Laudanosine Toxicity: A lipophilic tertiary amine metabolite that crosses the blood-brain barrier. At extremely high serum concentrations (following prolonged ICU infusions of atracurium > cisatracurium), laudanosine can stimulate the CNS and induce epileptiform seizure activity. Cisatracurium produces approximately 5 times less laudanosine than atracurium for equivalent neuromuscular block.

4. Pharmacologic Reversal: Anticholinesterases vs. Sugammadex

Recovery from neuromuscular blockade requires restoring functional neuromuscular transmission to ensure uncompromised pharyngeal tone, airway protection, and ventilatory mechanics.

Acetylcholinesterase Inhibitors (Anticholinesterases)

Anticholinesterases inhibit the enzyme acetylcholinesterase (AChE) in the synaptic cleft, preventing the breakdown of endogenous ACh. The resulting accumulation of ACh outcompetes non-depolarizing NMBAs at postjunctional nAChRs, shifting the concentration equilibrium toward channel opening.

$\text{Anticholinesterase} \xrightarrow{\text{Inhibits AChE}} [\text{ACh}]_{\text{synaptic}} \uparrow\uparrow \xrightarrow{\text{Competitive Displacement}} \text{Displaces Non-Depolarizer from } \alpha_1 \text{ Subunits}$

The Ceiling Effect

Once acetylcholinesterase is 100% inhibited, administering additional anticholinesterase cannot further increase ACh concentrations. Supramaximal dosing causes ACh to accumulate to levels that trigger postjunctional receptor desensitization and open-channel blockade, paradoxically worsening muscle weakness.

Anticholinesterase & Anticholinergic Pairing

Inhibiting AChE increases acetylcholine at both nicotinic and muscarinic receptors. To prevent severe muscarinic toxidrome (bradycardia, asystole, bronchoconstriction, increased airway secretions, miosis, hyperperistalsis), anticholinesterases must always be co-administered with an anticholinergic (antimuscarinic) agent whose pharmacokinetic onset matches the specific anticholinesterase.

Prerequisites for Neostigmine Reversal: Neostigmine should never be administered when there are 0 twitches on TOF. Administration requires a minimum of 2, and preferably 4, tactile twitches on TOF ($T_2 \ge 2$). Administering neostigmine during profound block (0–1 twitches) leads to delayed, incomplete reversal and significant postoperative residual neuromuscular weakness.

Sugammadex (Bridion): Cyclodextrin Encapsulation Pharmacology

Sugammadex is a synthetically modified $\gamma$-cyclodextrin consisting of 8 repeating glucopyranose units configured in a hollow, truncated cone. The interior cavity is lipophilic, while the exterior surface is rendered hydrophilic by 8 negatively charged carboxylate thio-ether side chains that electrostatically attract the quaternary ammonium groups of steroidal NMBAs.

Mechanism of Action: 1:1 Host-Guest Inclusion Complex

Sugammadex encapsulates free steroidal NMBA molecules in a 1:1 non-covalent stoichiometric complex within plasma. By binding free intravascular rocuronium with extraordinary affinity (association constant $K_a = 1.79 \times 10^7\text{ M}^{-1}$), sugammadex precipitously lowers free plasma rocuronium concentration to zero. This establishes a steep concentration gradient, driving rocuronium molecules off the postjunctional nAChRs back into the plasma, where they are irreversibly encapsulated.

NMBA Selectivity Spectrum

$\text{Binding Affinity: } \mathbf{Rocuronium} \gg \mathbf{Vecuronium} > \mathbf{Pancuronium}$

• Benzylisoquinolines: Sugammadex has zero affinity for cisatracurium, atracurium, or mivacurium. It is completely ineffective for benzylisoquinoline reversal.
• Succinylcholine: Sugammadex has zero affinity for succinylcholine.

Precise Weight-Based Dosing Guidelines (Actual Body Weight)

Sugammadex dosing must always be calculated using the patient's Actual Body Weight (ABW), not ideal body weight, to ensure adequate molecular encapsulation of the entire circulating drug volume.

Critical Drug Interactions & Clinical Warnings

1. Oral Contraceptive Interaction (Board Favorite): Sugammadex binds to progesterone and progestin-containing hormonal contraceptives (pills, implants, rings, injections), decreasing their circulating active levels.
   • Mandatory Patient Instruction: The patient must be informed that receiving sugammadex is equivalent to missing a daily oral contraceptive dose. Patients using hormonal contraceptives must use an additional non-hormonal barrier method (e.g., condoms) for 7 consecutive days following sugammadex administration.
2. Toremifene Displacement: Toremifene (a selective estrogen receptor modulator used in breast cancer) has high binding affinity for sugammadex and can displace rocuronium or vecuronium from the cyclodextrin cavity, causing recurarization.
3. Profound Bradycardia & Asystole: Rare cases of severe bradycardia and cardiac arrest have occurred within minutes of sugammadex injection. Continuous ECG monitoring is essential, and atropine must be immediately accessible.
4. Renal Impairment: Sugammadex and the rocuronium-sugammadex complex are excreted 100% unchanged by the kidneys via glomerular filtration. In severe renal disease ($CrCl < 30\text{ mL/min}$ or end-stage renal disease on dialysis), sugammadex is not recommended by the FDA due to prolonged complex retention (up to 7 days), although the complex remains stable and hemodialysis with high-flux filters clears the complex.
5. Coagulation Effects: Produces transient, minor increases in PT, PTT, and INR for up to 60 minutes after administration without clinically significant increases in postoperative bleeding.

---

5. Neuromuscular Monitoring Standards & Recovery Criteria

Objective quantitative monitoring is the standard of care to prevent residual neuromuscular blockade—a major cause of postoperative hypoxemia, airway obstruction, microaspiration, and reintubation.

Peripheral Nerve Stimulation Patterns

• Train-of-Four (TOF): Four 2-Hz electrical pulses (0.5 seconds apart). TOF Ratio is calculated as the amplitude of the fourth twitch divided by the first twitch ($T_4 / T_1$).
  • $T_4$ disappears at ~75% receptor occupancy.
  • $T_3$ disappears at ~80% receptor occupancy.
  • $T_2$ disappears at ~85% receptor occupancy.
  • $T_1$ disappears at ~90–95% receptor occupancy.
• Double Burst Stimulation (DBS): Two short 50-Hz tetanic bursts separated by 750 ms ($DBS_{3,3}$ or $DBS_{3,2}$). Tactile evaluation of fade is significantly easier than standard TOF, detecting residual fade down to TOF ratios of ~0.60.
• Post-Tetanic Count (PTC): 50-Hz tetany for 5 seconds, followed by a 3-second pause, then single 1-Hz twitches. Used during profound block (0 twitches on TOF) to quantify how close the patient is to the return of $T_1$.

Anatomic Monitoring Sites & Muscle Sensitivities

Extubation Criteria (Quantitative Standard)

Subjective clinical tests (e.g., 5-second head lift, sustained hand grip, inspiratory force $> -25\text{ cmH}_2\text{O}$, tongue protrusion) can be passed even when 50% to 70% of receptors remain blocked ($TOFR < 0.70$). The mandatory objective standard for safe extubation is a quantitative Train-of-Four Ratio (TOFR) $\ge 0.90$ (90%) measured at the adductor pollicis muscle.